Valuation : ENDRA Life Sciences Inc.

Market Cap 7.9M 6.82M 6.42M 5.85M 10.94M 747M 11.02M 76.05M 29.51M 382M 29.68M 29.03M 1.25B P/E 2026 *
-1.49x
P/E 2027 * -1.73x
Enterprise Value 7.9M 6.82M 6.42M 5.85M 10.94M 747M 11.02M 76.05M 29.51M 382M 29.68M 29.03M 1.25B EV / Sales 2026 *
-
EV / Sales 2027 * 39.5x
Free-Float
87.61%
Yield 2026 *
-
Yield 2027 * -
1 day+22.87%
1 week+17.46%
Current month+27.67%
1 month+52.87%
3 months+26.79%
6 months+63.01%
Current year+41.06%
1 week 4.81
Extreme 4.81
6.75
1 month 4.05
Extreme 4.05
6.75
Current year 2.96
Extreme 2.96
6.75
1 year 2.96
Extreme 2.96
9.85
3 years 2.9
Extreme 2.9
4,882.5
5 years 2.9
Extreme 2.9
72,100.07
10 years 2.9
Extreme 2.9
205,800.21
Manager TitleAgeSince
Chief Executive Officer 64 2024-08-12
Director of Finance/CFO 58 2024-08-07
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 59 2013-06-30
Director/Board Member 72 2014-12-31
Chairman 64 2024-08-12
Date Insider Type Main position Quantity % Market Cap. Importance
3/2/26 Free

Chief Executive Officer

26,921 2.3080%
3/2/26 Free

Chief Financial Officer

13,461 1.1540%
1/21/26 Free

Director

60,324 5.1716%
Change 5-day change 1-year change 3-year change Capi.($)
+22.87%+17.46%+49.30%-99.66% 7.9M
+0.97%-0.75%+3.51%+17.79% 49.74B
-1.08%-3.62%+425.30%+516.36% 44.98B
+1.59%+0.46%+42.97%+18.93% 42.52B
+0.72%-3.84%+8.83%+76.41% 40.78B
-0.90%-1.74%+15.20%+48.44% 32.89B
+2.01%+5.62% - - 17.09B
+0.37%-5.42%+23.70%+120.86% 16.28B
+1.70%-0.05%+18.53%+28.09% 14.4B
+1.56%-3.03%+77.46%+40.07% 13.48B
Average +2.99%-1.09%+73.87%+85.25% 27.22B
Weighted average by Cap. +0.57%-2.25%+92.87%+127.56%

Financials

2026 *2027 *
Net sales - 200K 173K 163K 148K 277K 18.89M 279K 1.92M 747K 9.66M 751K 735K 31.73M
Net income -6.1M -5.26M -4.96M -4.52M -8.44M -576M -8.51M -58.69M -22.78M -295M -22.91M -22.41M -968M -6.3M -5.44M -5.12M -4.66M -8.72M -595M -8.78M -60.61M -23.52M -304M -23.66M -23.14M -1B
Net Debt - -
Logo ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.
Employees
10
Date Price Change Volume
26-09-02 US$6.390 +21.25% 100,054
26-09-01 US$5.270 +5.29% 396,108
26-08-31 US$5.005 0.00% 1,167
26-08-28 US$5.005 -7.40% 24,533
26-08-27 US$5.405 -0.64% 9,880
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
5.270USD
Average target price
25.00USD
Spread / Average Target
+374.38%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NDRA Stock